 Home > Medical News > Medicines Company News > InnoCare completed the administration of the first adolescent patient with the second-generation pan-TRK inhibitor ICP-723

InnoCare completed the administration of the first adolescent patient with the second-generation pan-TRK inhibitor ICP-723

 Last Update: 2022-11-04
 Source: Internet
 Author: User

Tags

breast cancer tissue

new military tech

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On October 31, 2022, InnoCare (SSE: 688428; HKEx: 09969) today announced that the company's self-developed second-generation pan-TRK small molecule inhibitor ICP-723 has completed the first dose in adolescent patients in the Department of Pediatric Oncology, Sun Yat-sen University Cancer Prevention and Treatment Center, which is also the first clinical study
of ICP-723 in adolescent (12 to 18 years old) patients after showing good safety and efficacy in adult patients.

ICP-723 is a Class 1 innovative drug with independent intellectual property rights in the world, which is used to treat advanced or metastatic solid tumors carrying NTRK fusion genes, including breast, colorectal, lung, thyroid, sarcoma, etc.
, as well as patients
resistant to first-generation TRK inhibitors.

ICP-723 has shown good safety and efficacy
in NTRK fusion-positive patients treated at the recommended dose (RP2D) level of phase II.
Following the first clinical study in adolescent patients, InnoCare has also extended ICP-723 to pediatric patients (2 to 12 years of age).

Based on the Proof-of-Concept (POC) data obtained, InnoCare is committed to advancing the registration clinical study
of ICP-723 in China.
InnoCare has also conducted clinical studies of ICP-723 in the United States, and no dose-limiting toxicity (DLT)
has been observed in the first dose group.

Dr.
Jisong Cui, co-founder, chairman and CEO of InnoCare, said: "NTRK gene fusion occurs in adult, adolescent and pediatric cancer patients, especially in adolescents and children, and we will accelerate clinical trials to meet the unmet clinical needs
of adolescent and pediatric cancer patients.
"

About InnoCare

InnoCare (SSE: 688428; HKEx: 09969) is a commercial-stage biomedical high-tech company focusing on the development of a class of new drugs in the field of malignant tumors and autoimmune diseases, suitable for the treatment of lymphoma, solid tumors and autoimmune diseases
.
A number of new drug products are in the commercial, clinical and preclinical research and development stages
.
The company has branches
in Beijing, Nanjing, Shanghai, Guangzhou and the United States.

Abbreviations in English and Chinese

TRK: tropomyosin receptor kinase

NTRK: Neurotrophic tyrosine receptor kinase gene

={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.